125 Results

NICE recommends use of Fasenra in eosinophilic asthma.- AstraZeneca.

 Added 19 days ago

The National Institute for Health and Care Excellence has recommended that Fasenra (benralizumab), from AstraZeneca, be available to people with...

FDA approves ProAir Digihaler for asthma.- Teva.

 Added 1 month ago

Teva Pharmaceutical announced that the FDA has approved ProAir Digihaler (albuterol sulfate 117 mcg) inhalation powder, the first and only...

VR 475 did not meet endpoints in Phase III for treatment of asthma- Vectura

 Added 1 month ago

Vectura Group plc announces that its phase III study of VR 475 in adult and adolescent patients with severe uncontrolled...

GlaxoSmithKline files sBLA to expand indication of Nucala in eosinophilic asthma.- GSK.

 Added 2 months ago

GlaxoSmithKline announced the filing of a supplemental Biologics License Application (sBLA) to the FDA seeking an additional indication for the...

FDA approves Dupixent to treat moderate to severe asthma.-Sanofi + Regeneron.

 Added 3 months ago

The FDA has approved Dupixent (dupilumab) as add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older...

BORA trial shows long-term safety and efficacy of Fasenra in patients with eosinophilic asthma.-AstraZeneca

 Added 4 months ago

AstraZeneca announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as...

ERS 2018 | Pollution linked to new dangers for unborn babies

 Added 4 months ago

First evidence that soot from polluted air is reaching placenta.

Nucala study in eosinophilic asthma published in JACI.- GSK.

 Added 4 months ago

GlaxoSmithKline announced results from an indirect treatment comparison of the licensed doses of Nucala (mepolizumab), versus benralizumab and reslizumab in...

European Commission approves Nucala an add-on treatment for severe refractory eosinophilic asthma in paediatric patients aged six up to 17 years.- GSK

 Added 4 months ago

GlaxoSmithKline (announced that the European Commission has granted marketing authorisation for Nucala (mepolizumab) as an add-on treatment for severe refractory...

CHMP recommends Nucala as adjunctive treatment for severe refractory eosinophilic asthma in children aged 6 to 17 years. - GSK.

 Added 5 months ago

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of mepolizumab (Nucala) from GlaxoSmithKline as adjunctive treatment...

Load more